Partnerships, Licensing, Investments and M&A Deals and Trends for 2016 in Pharmaceuticals

Powered by

All the vital news, analysis, and commentary curated by our industry experts.

$3500

GlobalData's “Partnerships, Licensing, Investments and M&A Deals and Trends for 2016 in Pharmaceuticals” report is an essential source of data and trend analysis on partnerships, licensing, mergers and acquisitions (M&As) and financings in the pharmaceuticals industry. The report provides detailed information on partnership and licensing transactions, M&As, equity/debt offerings, private equity, and venture financing registered in the pharmaceuticals industry in 2016. The report portrays detailed comparative data on the number of deals and their value in the last five years, subdivided by deal types, various therapy areas, and geographies. Additionally, the report provides information on the top financial advisory firms in the pharmaceuticals industry.
Data presented in this report is derived from GlobalData’s proprietary in-house Pharmaceuticals eTrack deals database and primary and secondary research

Scope

Analysis of the market trends for the pharmaceutical industry in the global arena.

Review of deal trends in the cardiovascular, central nervous system, dermatology, ear nose throat disorders, gastrointestinal, genito urinary system and sex hormones, hematological disorders, hormonal disorders, immunology, infectious disease, male health, metabolic disorders, mouth and dental disorders, musculoskeletal, oncology, ophthalmology, respiratory, toxicology, and women's health segments.

Analysis of partnerships, licensing, M&As, equity/debt offerings, private equity, and venture financing deals in the pharmaceutical industry.

Analysis of therapy areas which are very active in terms of venture capital financing, partnerships, licensing agreements, equity/debt offerings, and M&As.

Analysis of deals based on different payment modes, including upfront and milestone payments, primarily in partnerships and licensing agreements in the pharmaceutical industry.

Analysis of partnership and licensing deals based on clinical stage of development of products.

Summary of the pharmaceutical deals globally in the five years.

Information on the top deals happened in the pharmaceutical industry.

Geographies covered include – North America, Europe, Asia Pacific, South & Central America, and the Middle East & Africa.

League tables of financial advisors in M&As and equity/debt offerings. This includes key advisors such as Morgan Stanley, Credit Suisse, and Goldman Sachs

Reasons to Buy

Enhance your decision making capability in a more rapid and time sensitive manner.

Find out the major deal performing segments for investments in your industry.

Evaluate the types of companies which are entering into partnership or licensing agreements; divesting and acquiring assets.

Identify companies that are aggressively looking to raise capital in the market

Evaluate niche therapy areas that are receiving majority of the upfront and milestone payments in the pharmaceutical industry.

Identify the key venture capitalists, who are financing the pharmaceutical and biotech companies.

Evaluate the clinical development stages where majority of the partnerships and licensing agreements are happening.

Do deals with an understanding of how competitors are financed, and the mergers and partnerships that have shaped the pharmaceutical industry.

Identify growth segments and opportunities in each region within the industry.

Look for key financial advisors where you are planning to raise capital from the market or for acquisitions within the industry.

Table of Contents

1 Table of Contents 2

1.1 List of Tables 6

1.2 List of Figures 9

2 Pharmaceutical & Healthcare, Global, Deals Summary 13

2.1 Pharmaceutical & Healthcare, Global, Deals Analysis, 2016 13

2.1.1 Pharmaceuticals & Healthcare, Global, Deals Analysis, 2016 by Quarter 14

2.2 Pharmaceuticals & Healthcare, Global, by Type, Number of Deals, 2016 16

2.3 Pharmaceuticals & Healthcare, Global, by Type, Deal Values, 2016 17

2.4 Pharmaceuticals & Healthcare, Global, Top Deals, 2016 18

2.5 Pharmaceuticals & Healthcare, Top Deals, Global, Summaries, 2016 18

2.5.1 Bayer to Acquire Monsanto for USD66 Billion 18

2.5.2 Shire Acquires Baxalta for USD32 Billion 19

2.5.3 Abbott Labs Prices Public Offering of Notes for USD15.1 Billion 20

2.5.4 Teva Pharma Raises USD15 Billion in Public Offering of Notes 20

2.5.5 Pfizer Acquires Medivation in Tender Offer 20

2.5.6 Shire Raises USD12.1 Billion in Public Offering of Notes 21

2.5.7 Mylan Acquires Meda for USD9.9 Billion 22

2.5.8 AbbVie Acquires Stemcentrx 22

2.5.9 AbbVie to Raise USD7.8 Billion in Public Offering of Notes 23

2.5.10 Pfizer Raises USD6 Billion in Public Offering of Notes 23

3 Pharmaceuticals & Healthcare, Global, Top Deal Makers, 2016 24

4 Pharmaceuticals & Healthcare, Global, Deal Summary, by Type 25

4.1 Pharmaceuticals & Healthcare, Global, M&A, 2016 25

4.1.1 Pharmaceuticals & Healthcare, Global, M&A, 2016 by Quarter 26

4.1.2 Top M&A Deals in 2016 27

4.1.3 Pharmaceuticals & Healthcare, Global, M&A Deals, by Therapy Area, 2016 28

4.2 Pharmaceuticals & Healthcare, Global, Equity Offering Deals, 2016 29

4.2.1 Pharmaceuticals & Healthcare, Global, Equity Offering Deals, 2016 by Quarter 30

4.2.2 Pharmaceuticals & Healthcare, Global, IPO Deals, 2016 31

4.2.3 Top IPOs in 2016 32

4.2.4 Pharmaceuticals & Healthcare, Global, Secondary Offerings Deals, 2016 32

4.2.5 Top Secondary Offerings in 2016 33

4.2.6 Pharmaceuticals & Healthcare, Global, PIPE Deals, 2016 34

4.2.7 Top PIPE Deals in 2016 35

4.2.8 Pharmaceuticals & Healthcare, Global, Equity Offering Deals, by Therapy Area, 2016 35

4.3 Pharmaceuticals & Healthcare, Global, Debt Offering Deals, 2016 36

4.3.1 Pharmaceuticals & Healthcare, Global Debt Offerings, 2016 by Quarter 37

4.3.2 Pharmaceuticals & Healthcare, Global, Public Debt Offerings, 2016 38

4.3.3 Top Public Debt Offerings in 2016 39

4.3.4 Pharmaceuticals & Healthcare, Global, Private Debt Placements, 2016 39

4.3.5 Top Private Debt Placements in 2016 41

4.3.6 Pharmaceuticals & Healthcare, Global, Debt Offering Deals, by Therapy Area, 2016 41

4.4 Pharmaceuticals & Healthcare, Global, Partnership Deals, 2016 42

4.4.1 Pharmaceuticals & Healthcare, Global, Partnership Deals, 2016 by Quarter 43

4.4.2 Pharmaceuticals & Healthcare, Global, Partnership Deals, by Therapy Area, 2016 45

4.4.3 Pharmaceuticals & Healthcare, Global, Partnership Deals, by Upfront & Milestone Payments and Deal Value (US$ m), 2016 46

4.4.4 Pharmaceuticals & Healthcare, Global, Partnership Deals, by Therapy Area, by Upfront & Milestone Payments and Deal Values (US$ m), 2016 47

4.4.5 Pharmaceuticals & Healthcare, Global, Partnership Deals, by Phase, Number Of Deals, 2016 48

4.4.6 Pharmaceuticals & Healthcare, Global, Partnership Deals, by Phase, Deal Values (US$ m), 2016 48

4.4.7 Pharmaceuticals & Healthcare, Global, Partnership Deals, by Phase, by Upfront & Milestone Payments and Deal Values (US$ m), 2016 50

4.4.8 Pharmaceuticals & Healthcare, Global, Top Partnership Deals, by Deal Values, 2016 51

4.4.9 Pharmaceuticals & Healthcare, Global, Top Partnership Deals, by Upfront Payment, 2016 52

4.4.10 Pharmaceuticals & Healthcare, Global, Top Partnership Deals, by Milestone Payment, 2016 52

4.5 Pharmaceuticals & Healthcare, Global, Licensing Agreements, 2016 53

4.5.1 Pharmaceuticals & Healthcare, Global, Licensing Agreements, 2016 by Quarter 54

4.5.2 Pharmaceuticals & Healthcare, Global, Licensing Agreements, by Therapy Area, 2016 54

4.5.3 Pharmaceuticals & Healthcare, Global, Licensing Agreements, by Upfront & Milestone Payments and Deal Value (US$ m), 2016 56

4.5.4 Pharmaceuticals & Healthcare, Global, Licensing Agreements, by Therapy Area, by Upfront & Milestone Payments and Deal Values (US$ m), 2016 57

4.5.5 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Phase, Total Deal Values (US$ m), 2016 58

4.5.6 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Phase, Total Deal Values (US$ m), 2016 59

4.5.7 Pharmaceuticals & Healthcare, Global, Licensing Agreements, by Phase, by Upfront & Milestone Payments and Deal Values (US$ m), 2016 61

4.5.8 Pharmaceuticals & Healthcare, Global, Top Licensing Agreements, by Deal Values, 2016 62

4.5.9 Pharmaceuticals & Healthcare, Global, Top Licensing Agreements, by Upfront Payment, 2016 63

4.5.10 Pharmaceuticals & Healthcare, Global, Top Licensing Agreements, by Milestone Payment, 2016 63

4.6 Pharmaceuticals & Healthcare, Global, Private Equity Deals, 2016 64

4.6.1 Pharmaceuticals & Healthcare, Global, Private Equity Deals, 2016 by Quarter 64

4.6.2 Top Private Equity Deals in 2016 66

4.6.3 Pharmaceuticals & Healthcare, Global, Private Equity Deals, by Therapy Area, 2016 66

4.7 Pharmaceuticals & Healthcare, Global, Venture Capital Deals, 2016 68

4.7.1 Pharmaceuticals & Healthcare, Global, Venture Financing Deals, 2016 by Quarter 69

4.7.2 Pharmaceuticals & Healthcare, Global, Venture Capital Deals, by Stage of Financing, 2016 70

4.7.3 Pharmaceuticals & Healthcare, Global, Venture Capital Deals, by Stage of Financing, 2016 70

4.7.4 Pharmaceuticals & Healthcare, Global, Venture Capital, by Therapy Area, 2016 71

4.7.5 Pharmaceuticals & Healthcare, Global, Top VC Backed Companies, Last One Year 72

4.7.6 Pharmaceuticals & Healthcare, Global, Top Venture Financing Firms, 2016 73

4.7.7 Top Venture Financing Deals in 2016 75

5 Pharmaceuticals & Healthcare, Global, Deal Summary, By Market 76

5.1 Pharmaceuticals & Healthcare, Global, Oncology Deals, 2016 76

5.1.1 Pharmaceuticals & Healthcare, Global, Oncology Deals, 2016 by Quarter 77

5.1.2 Oncology – Deals of the Year 78

5.2 Pharmaceuticals & Healthcare, Global, Central Nervous System Deals, 2016 82

5.2.1 Pharmaceuticals & Healthcare, Global, Central Nervous System Deals, 2016 by Quarter 83

5.2.2 Central Nervous System – Deals of the Year 84

5.3 Pharmaceuticals & Healthcare, Global, Infectious Disease Deals, 2016 87

5.3.1 Pharmaceuticals & Healthcare, Global, Infectious Disease Deals, 2016 by Quarter 89

5.3.2 Infectious Disease – Deals of the Year 90

5.4 Pharmaceuticals & Healthcare, Global, Immunology Deals, 2016 92

5.4.1 Pharmaceuticals & Healthcare, Global, Immunology Deals, 2016 by Quarter 94

5.4.2 Immunology – Deals of the Year 95

5.5 Pharmaceuticals & Healthcare, Global, Cardiovascular Deals, 2016 97

5.5.1 Pharmaceuticals & Healthcare, Global, Cardiovascular Deals, 2016 by Quarter 98

5.5.2 Cardiovascular – Deals of the Year 99

5.6 Pharmaceuticals & Healthcare, Global, Metabolic Disorders Deals, 2016 101

5.6.1 Pharmaceuticals & Healthcare, Global, Metabolic Disorders Deals, 2016 by Quarter 103

5.6.2 Metabolic Disorders – Deals of the Year 104

5.7 Pharmaceuticals & Healthcare, Global, Gastrointestinal Deals, 2016 106

5.7.1 Pharmaceuticals & Healthcare, Global, Gastrointestinal Deals, 2016 by Quarter 107

5.7.2 Gastrointestinal – Deals of the Year 109

6 Pharmaceuticals & Healthcare, Deal Summary, By Geography 112

6.1 Pharmaceuticals & Healthcare, North America Region, Deals, 2016 112

6.1.1 Pharmaceuticals & Healthcare, North America Region, Deals, 2016 by Quarter 113

6.1.2 North America – Deals of the Year 114

6.2 Pharmaceuticals & Healthcare, European Region Deals, 2016 118

6.2.1 Pharmaceuticals & Healthcare, Europe, Deals, 2016 by Quarter 119

6.2.2 Europe – Deals of the Year 120

6.3 Pharmaceuticals & Healthcare, Asia-Pacific Region, Deals, 2016 124

6.3.1 Pharmaceuticals & Healthcare, Asia-Pacific Region Deals, 2016 by Quarter 125

6.3.2 Asia-Pacific – Deals of the Year 126

6.4 Pharmaceuticals & Healthcare, Rest of the World (ROW) Deals, 2016 129

6.4.1 Pharmaceuticals & Healthcare, Rest of the World Deals, 2016 by Quarter 130

6.4.2 Rest of the World – Deals of the Year 131

7 Pharmaceuticals & Healthcare, Global, Top Financial Advisors 133

7.1 Pharmaceuticals & Healthcare, Global, Top Financial Advisors, M&A, 2016 133

7.2 Pharmaceuticals & Healthcare, Global, Top Financial Advisors, Equity Offerings, 2016 134

8 Further Information 136

8.1 Methodology 136

8.2 About GlobalData 137

8.3 Contact Us 137

8.4 Disclosure information 137

8.5 Disclaimer 138

Frequently asked questions

Partnerships, Licensing, Investments and M&A Deals and Trends for 2016 in Pharmaceuticals thematic reports
Currency USD
$3,500

Can be used by individual purchaser only

$10,500

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company


Undecided about purchasing this report?

Enquire Before Buying

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.

See what our customers are saying

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

Senior Account Manager, TSYS
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at Partnerships, Licensing, Investments and M&A Deals and Trends for 2016 in Pharmaceuticals in real time.

  • Access a live Partnerships, Licensing, Investments and M&A Deals and Trends for 2016 in Pharmaceuticals dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.